Literature DB >> 11342902

Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.

J Palou1, P Laguna, F Millán-Rodríguez, R R Hall, J Salvador-Bayarri, J Vicente-Rodríguez.   

Abstract

PURPOSE: Intravesical instillations of bacillus Calmette-Guerin have demonstrated satisfactory results in the treatment of vesical carcinoma in situ and high grade superficial bladder tumors. We designed a protocol to evaluate the decrease in tumor recurrence with maintenance therapy.
MATERIALS AND METHODS: Between June 1989 and May 1995 an initial course of 6 intravesical instillations of Connaught strain bacillus Calmette-Guerin was administered in patients with carcinoma in situ and/or high grade superficial bladder tumors. Six months later 131 disease-free patients were randomly assigned to a control group or a maintenance therapy group that received 6 instillations every 6 months (6 x 6) for a 2-year period.
RESULTS: Of the 126 evaluable patients at a mean followup of 79 months there were no significant differences in recurrence nor progression. A total of 16 patients (26.2%) in the control and 10 (15.1%) in the maintenance group had superficial relapse at a mean of 24 and 20 months, respectively (p = 0.07). Eight patients underwent radical cystectomy due to bladder contraction in 1, high grade superficial recurrence in 4 and disease progression in 3. Of the 65 patients on maintenance therapy 22 (33.85%) completed the planned 2-year treatment.
CONCLUSIONS: Six-month maintenance therapy in patients treated initially for carcinoma in situ and/or high grade superficial bladder tumors who are disease-free at 6 months did not significantly decrease recurrence or progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342902

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.

Authors:  Alon Z Weizer; Christopher Tallman; Jeffrey S Montgomery
Journal:  World J Urol       Date:  2010-11-28       Impact factor: 4.226

Review 2.  New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.

Authors:  Ali Ghasemzadeh; Trinity J Bivalacqua; Noah M Hahn; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-12-18       Impact factor: 12.531

Review 3.  [Uro-oncology--update 2009].

Authors:  T Otto
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

Review 4.  Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.

Authors:  Daher C Chade; Shahrokh F Shariat; Guido Dalbagni
Journal:  Int Braz J Urol       Date:  2009 Nov-Dec       Impact factor: 1.541

Review 5.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

Review 6.  Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.

Authors:  Ashish M Kamat; Thomas W Flaig; H Barton Grossman; Badrinath Konety; Donald Lamm; Michael A O'Donnell; Edward Uchio; Jason A Efstathiou; John A Taylor
Journal:  Nat Rev Urol       Date:  2015-03-24       Impact factor: 14.432

7.  Cyclin D3 gene amplification in bladder carcinoma in situ.

Authors:  Antonio Lopez-Beltran; Jose L Ordóñez; Ana P Otero; Ana Blanca; Vicky Sevillano; Marta Sanchez-Carbayo; Elisa Muñoz; Liang Cheng; Rodolfo Montironi; Enrique de Alava
Journal:  Virchows Arch       Date:  2010-09-07       Impact factor: 4.064

Review 8.  Immunobiology and immunotherapy in genitourinary malignancies.

Authors:  Marinos Tsiatas; Petros Grivas
Journal:  Ann Transl Med       Date:  2016-07

9.  Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute.

Authors:  Koo Han Yoo; Tae Joon Lim; Sung-Goo Chang
Journal:  Exp Ther Med       Date:  2011-12-01       Impact factor: 2.447

10.  Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer.

Authors:  Ashish M Kamat; Sima Porten
Journal:  Eur Urol       Date:  2013-10-26       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.